| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 data readout example | Retifanlimab (Zynyz®) SCAC - final/trial completion data from POD1UM‑303/InterAACT 2 (supporting registrational dataset) | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 3 data readout example | Retifanlimab (Zynyz®) SCAC - final/trial completion data from POD1UM‑303/InterAACT 2 (supporting registrational dataset) | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | |
Phase 3 data readout example | Retifanlimab (Zynyz®) SCAC - final/trial completion data from POD1UM‑303/InterAACT 2 (supporting registrational dataset) | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Incyte Corporation$116.71
-1.92 (-1.62%)
A 81Pipeline Score Undervalued Biotech · Commercial
Market Cap
19.41 B
EPS
7.29
P/E Ratio
13.74 $
Value Trade
220.83 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.27 B
R&D Expenses
515.90 M
Operating CF
369.35 M
Total Assets
7.34 B
Total Liabilities
1.72 B
Equity
5.62 B
D/E Ratio
12,345
-0.29 %
Week
0.14 %
1 Month
-4.4 %
3 Month
-4.75 %
6 Month
15.68 %
5 Year
5,081.87 %
All Time
Cash Data
Cash Position
4.02 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 28, 2026
Overview
Volume
1.64 M
52 Week Range
63.93 - 112.29
% held by Insiders
0.93 %
% held by Institutions
105.83 %
Enterprise Value
15.43 B
Total Shares
199.09 M
Short %
6.36 %
Float Shares
166.24 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Incyte Corporation
523Total events
17Upcoming
267Tier-1 (high impact)
2019 – 2026Coverage
Upcoming catalysts 17
Q4 2026
T1Topline Readout
Topline results from Phase 3 TRuE-HS1 and TRuE-HS2 studies of ruxolitinib cream in HS
2026-H1
T1NDA Submission
Planned sBLA submission for tafasitamab + lenalidomide + R-CHOP in first-line DLBCL
TBD
T2Oral Presentation
frontMIND data to be submitted for presentation at upcoming scientific meeting
2026-H2
T1Topline Readout
Phase 2 proof-of-concept topline data for povorcitinib in asthma anticipated
Event history 506
Jun 26, 2026
▲CHMP Positive OpinionRuxolitinibApprovedEx-US Regulatory
Positive CHMP opinion for Opzelura cream in moderate atopic dermatitis
moderate atopic dermatitissource ↗
Jun 19, 2026
▲EU ApprovalTafasitamabApprovedEx-US Regulatory
Incyte Japan announces approval of Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory DLBCL
relapsed or refractory diffuse large B-cell lymphoma (DLBCL)source ↗
Jun 15, 2026
▲Oral PresentationINCA033989Presentation
Positive Daten zu INCA033989 auf der EHA 2026 präsentiert
Myelofibrose; essenzielle Thrombozythämiesource ↗
Jun 15, 2026
◆Oral PresentationTafasitamabApprovedPresentation
Phase 3 frontMIND trial results presented at EHA 2026 plenary session
relapsed/refractory diffuse large B-cell lymphomasource ↗
Jun 13, 2026
▲Oral PresentationTafasitamabApprovedPresentation
Results from Phase 3 frontMIND trial of Tafasitamab combination presented at EHA 2026 Congress Plenary
Relapsed/Refractory Diffuse Large B-Cell Lymphomasource ↗
Jun 13, 2026
▲Oral PresentationINCA033989Presentation
Positive data presented at EHA 2026 for INCA033989 in essential thrombocythemia
Essential Thrombocythemiasource ↗
Jun 8, 2026
▲AcquiredCorporate
Incyte to acquire Vega Therapeutics for $1.25B upfront plus up to $750M in sales milestones
Jun 8, 2026
Jun 8, 2026
◆AcquisitionCorporate
Incyte to acquire Vega Therapeutics for $1.25B upfront plus up to $750M in milestones
Jun 1, 2026
▲Primary Endpoint MetTafasitamabApprovedClinical Data
frontMIND study met primary endpoint: significant improvement in progression-free survival
diffuse large B-cell lymphomasource ↗
Drug Pipeline Intelligence
A81
Pipeline Score $23.8B
Pipeline ValueUndervalued
Valuation Signal76
Drugs Scored4.1x
rNPV / MCap Top 97%
Mid Cap (rank 28 of 911)
Percentile RankIncyte Corporation earns an A-grade pipeline score (81/100), with $28.0B risk-adjusted pipeline value, led by INCB013739 in Diabetes Mellitus, Type 2 (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INCB013739 Small molecule | Type 2 Diabetes | Phase 2 | NCT00698230 | 23% | $4.7B | COMPLETED | 302 | - | - | May 1, 2009 | - | Feb 14, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
INCA033989 Breakthrough | Myelofibrose und essenzielle Thrombozythämie | — | 2026-06-15 | schnelle, robuste und anhaltende klinische und molekulare Reaktionen Read More | Incyte gibt auf der EHA 2026 neue positive Daten bekannt, wonach INCA033989 bei Patienten mit Myelofibrose und essenzieller Thrombozythämie schnelle, robuste und anhaltende klinische und molekulare Reaktionen erzielte und gut vertragen wurde Read More | |
INCA033989 Breakthrough | Myelofibrose und essenzielle Thrombozythämie | — | 2026-06-15 | schnelle, robuste und anhaltende klinische und molekulare Reaktionen Read More | Incyte gibt auf der EHA 2026 neue positive Daten bekannt, wonach INCA033989 bei Patienten mit Myelofibrose und essenzieller Thrombozythämie schnelle, robuste und anhaltende klinische und molekulare Reaktionen erzielte und gut vertragen wurde Read More | |
INCA033989 Breakthrough | Myelofibrose und essenzielle Thrombozythämie | — | 2026-06-15 | schnelle, robuste und anhaltende klinische und molekulare Reaktionen Read More | Incyte gibt auf der EHA 2026 neue positive Daten bekannt, wonach INCA033989 bei Patienten mit Myelofibrose und essenzieller Thrombozythämie schnelle, robuste und anhaltende klinische und molekulare Reaktionen erzielte und gut vertragen wurde Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INCY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INCY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-07-17 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INCY▼ -1.6%today
Incyte to Report Second Quarter Financial Results
Incyte has announced a conference call and webcast to discuss its second quarter financial results for 2026. The event is scheduled for July 28, 2026, with the press release set to be issued at 7:00 a.m. ET. This initiative demonstrates the company's commitment to keeping investors informed.
Read more →INCYIncyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
Incyte has successfully completed the acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics. This strategic move is aimed at expanding Incyte's hematology portfolio, thereby enhancing its capabilities and market presence in this therapeutic area. The acquisition is expected to contribute positively to Incyte's growth trajectory.
Read more →INCYResumen: Incyte anuncia un dictamen favorable del CHMP sobre la crema Opzelura® (ruxolitinib) para tratar a los pacientes adultos con dermatitis atópica moderada
Incyte has announced a favorable opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding its cream Opzelura® (ruxolitinib). This treatment is aimed at adult patients suffering from moderate atopic dermatitis. The positive opinion may lead to expanded treatment options for this patient demographic.
Read more →INCYRiassunto: Incyte annuncia l'opinione positiva del CHMP per Opzelura® (ruxolitinib) crema per il trattamento della dermatite atopica moderata in pazienti adulti
Incyte has received a positive opinion from the CHMP regarding Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis in adult patients. This development highlights the potential of Opzelura® to address an unmet medical need in this patient population. The approval could enhance Incyte's standing in the biopharma market.
Read more →INCYSamenvatting: Incyte kondigt positief CHMP-advies aan voor Opzelura® (ruxolitinib)-crème voor de behandeling van volwassenen met matige atopische dermatitis
Incyte has announced a positive opinion from the CHMP regarding Opzelura (ruxolitinib) cream. This treatment is intended for adults suffering from moderate atopic dermatitis. The favorable opinion could significantly improve available treatment options for this patient population.
Read more →INCYIncyte gibt positive Stellungnahme des CHMP zu Opzelura ® (Ruxolitinib)-Creme zur Behandlung von Erwachsenen mit mittelschwerer atopischer Dermatitis bekannt
Incyte announced a positive opinion from the CHMP regarding Opzelura® (Ruxolitinib) cream. This treatment is aimed at adults suffering from moderate atopic dermatitis. The favorable feedback could enhance the drug's market potential and accessibility for patients.
Read more →INCY▲ +5.8%on this newsshared move
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
Incyte has received a positive opinion from the CHMP regarding its product Opzelura® (ruxolitinib) cream. This recommendation is aimed at treating adults suffering from moderate atopic dermatitis. The positive opinion marks a significant advancement in the regulatory process, potentially leading to approval for this new treatment option.
Read more →INCY▲ +5.5%on this news
Samenvatting: Incyte Japan maakt de goedkeuring bekend van Minjuvi® (tafasitamab) in combinatie met lenalidomide voor de behandeling van volwassenen met recidiverend of refractair DLBCL (diffuus grootcellig B-cellymfoom)
Incyte Japan has announced the approval of Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval marks a significant advancement in treatment options for this patient population. Further details on the implications of this approval were not provided.
Read more →INCY▲ +5.5%on this news
Riassunto: Incyte Japan annuncia l'approvazione di Minjuvi® (tafasitamab) in combinazione con lenalidomide per il trattamento di pazienti adulti con linfoma diffuso a grandi cellule B (DLBCL) recidivante o refrattario
Incyte Japan has announced the approval of Minjuvi® (tafasitamab) in combination with lenalidomide for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval represents a significant advancement in treatment options for this patient population. The combination therapy aims to improve outcomes for those affected by this aggressive form of lymphoma.
Read more →INCY▲ +5.5%on this newsshared move
Incyte Japan gibt Zulassung von Minjuvi® (Tafasitamab) in Kombination mit Lenalidomid zur Behandlung von Erwachsenen mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom (DLBCL) bekannt
Incyte has announced the approval of Minjuvi® (Tafasitamab) in Japan, in combination with Lenalidomid, for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval provides a new therapeutic option for patients facing this challenging condition. The combination aims to enhance treatment efficacy for DLBCL.
Read more →INCY▲ +5.5%on this newsshared move
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Incyte Japan has announced the approval of Minjuvi® (tafasitamab) in combination with Lenalidomide for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This approval marks a significant advancement in treatment options for patients facing this challenging condition. The combination therapy aims to improve patient outcomes and address unmet medical needs.
Read more →INCYRiassunto: Incyte annuncia che i nuovi dati positivi presentati all'EHA 2026 hanno mostrato che INCA033989 ha ottenuto risposte cliniche e molecolari rapide, solide e sostenute ed è stato ben tollerato in pazienti con mielofibrosi e trombocitemia essenziale
Incyte has announced positive new data regarding INCA033989, presented at EHA 2026. The data indicates that the treatment has achieved rapid, solid, and sustained clinical and molecular responses in patients with myelofibrosis and essential thrombocythemia. Additionally, the treatment has demonstrated good tolerability among patients.
Read more →INCYSamenvatting: Incyte maakt op EHA 2026 nieuwe positieve resultaten bekend: INCA033989 leidde tot snelle, krachtige en aanhoudende klinische en moleculaire responsen en werd goed verdragen door patiënten met myelofibrose en essentiële trombocytemie
Incyte announced positive results for INCA033989 at EHA 2026, highlighting its rapid and sustained clinical and molecular responses in patients with myelofibrosis and essential thrombocythemia. The treatment demonstrated good tolerability among patients, marking a significant advancement in therapeutic options for these conditions.
Read more →INCYResumen: Incyte anuncia que los nuevos datos positivos en EHA 2026 demostraron que INCA033989 logró respuestas clínicas y moleculares rápidas, robustas y sostenidas, y fue bien tolerado por pacientes con mielofibrosis y trombocitemia esencial
Incyte announced positive new data from EHA 2026 regarding INCA033989, which demonstrated rapid, robust, and sustained clinical and molecular responses in patients with myelofibrosis and essential thrombocythemia. The treatment was well tolerated, indicating its potential effectiveness in these conditions.
Read more →INCYIncyte annonce de nouvelles données positives à l'EHA 2026 qui indiquent qu'INCA033989 a obtenu des réponses cliniques et moléculaires rapides, robustes et soutenues et a été bien toléré chez les patients atteints de myélofibrose...
Incyte has announced positive new data at EHA 2026 regarding INCA033989, which demonstrated rapid and robust clinical and molecular responses in patients with myelofibrosis. The treatment was also well tolerated, suggesting a favorable safety profile. These findings contribute to the growing evidence supporting INCA033989's efficacy.
Read more →INCYIncyte gibt auf der EHA 2026 neue positive Daten bekannt, wonach INCA033989 bei Patienten mit Myelofibrose und essenzieller Thrombozythämie schnelle, robuste und anhaltende klinische und molekulare Reaktionen erzielte und gut vertragen wurde
Incyte presented new positive data at EHA 2026 regarding INCA033989. The treatment demonstrated rapid, robust, and sustained clinical and molecular responses in patients with myelofibrosis and essential thrombocythemia. Additionally, it was reported to be well tolerated by the patients involved in the study.
Read more →INCYRiassunto: I risultati dello studio clinico pivotale di Fase 3 frontMIND di Incyte sulla combinazione di Tafasitamab (Monjuvi®/Minjuvi®) presentati in occasione della sessione plenaria del congresso 2026 della European Hematology Association (EHA)...
The article discusses the pivotal Phase 3 frontMIND clinical trial results for Tafasitamab (Monjuvi/Minjuvi) presented at the 2026 European Hematology Association congress. However, specific details regarding the results or implications are not provided in the text.
Read more →INCYSamenvatting: De resultaten van Incyte’s cruciale fase 3-studie frontMIND naar de combinatiebehandeling met tafasitamab (Monjuvi® /Minjuvi®) werden gepresenteerd tijdens de plenaire sessie van het congres van de European Hematology Association (EHA)...
Incyte's phase 3 study results for the combination treatment with tafasitamab were presented at the European Hematology Association congress. The details of the findings and their implications for treatment were discussed during the plenary session.
Read more →INCYResumen: Los resultados del ensayo fundamental frontMIND fase 3 de la combinación tafasitamab (Monjuvi®/Minjuvi®) de Incyte presentados en el plenario del Congreso de la Asociación Europea de Hematología (EHA) 2026...
The article discusses the presentation of phase 3 trial results for tafasitamab at the European Hematology Association Congress 2026. However, specific details about the results or implications are not provided in the text. The focus appears to be on the event rather than the findings themselves.
Read more →INCYLes résultats de l’essai pivot de phase 3 frontMIND mené par Incyte sur l’association thérapeutique à base de tafasitamab (Monjuvi®/Minjuvi®), présentés lors de la séance plénière du congrès 2026 de l’Association européenne d’hématologie (EHA)...
Incyte presented results from the phase 3 frontMIND trial on tafasitamab (Monjuvi/Minjuvi) at the 2026 EHA congress. The details of the trial outcomes and implications for treatment were highlighted, but specific results were not disclosed in the provided text.
Read more →INCYErgebnisse der zulassungsrelevanten Phase-3-Studie „frontMIND“ von Incyte zur Kombination von Tafasitamab (Monjuvi® /Minjuvi® ), die auf der Plenarsitzung des Kongresses der European Hematology Association (EHA) 2026 vorgestellt wurden...
Incyte presented results from the Phase 3 study 'frontMIND' regarding Tafasitamab (Monjuvi/Minjuvi) at the European Hematology Association Congress 2026. The study's findings are expected to contribute to the understanding of Tafasitamab's efficacy in combination therapy. Further details on the results were not provided in the article.
Read more →INCY▼ -6%on this newsshared move
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
Incyte has announced promising new data regarding INCA033989 at the EHA 2026 conference. The data indicates that the treatment achieved rapid and robust clinical and molecular responses in patients with myelofibrosis and essential thrombocythemia. Additionally, the treatment was reported to be well tolerated, highlighting its potential benefits.
Read more →INCY▼ -6%on this newsshared move
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
Incyte presented results from the pivotal Phase 3 frontMIND trial of Tafasitamab at the 2026 EHA Congress. The trial showed prolonged progression-free survival for patients receiving Tafasitamab in combination therapy. Further details on the trial's outcomes and implications for treatment were discussed during the plenary session.
Read more →INCYIncyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
Incyte (Nasdaq: INCY) has announced its definitive agreement to acquire Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion, with potential total payments of up to $2 billion based on sales milestones. This acquisition adds the promising monoclonal antibody VGA039 to Incyte's portfolio, which targets Protein S and is in Phase 3 development for von Willebrand disease. The FDA has granted VGA039 multiple designations that could facilitate its development and market entry. The transaction awaits regulatory approvals and is expected to finalize in Q3 of 2026.
Read more →INCYIncyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
Incyte announced positive results from the Phase 3 frontMIND trial, showing that the combination of tafasitamab and lenalidomide with R-CHOP significantly prolonged progression-free survival in previously untreated high-risk DLBCL patients. The trial demonstrated a 25% reduction in the risk of disease progression or death. The findings suggest a potential new standard of care for this patient population, with the data set to be presented at the 2026 ASCO Annual Meeting.
Read more →INCYDie zulassungsrelevante frontMIND-Studie von Incyte zeigte, dass die Kombination mit Tafasitamab (Monjuvi®/Minjuvi®) das progressionsfreie Überleben signifikant verlängerte und das Risiko eines Krankheitsfortschritts oder des Todes bei Patienten...
Die frontMIND-Studie von Incyte hat gezeigt, dass die Kombination von Tafasitamab mit anderen Therapien das progressionsfreie Überleben signifikant verlängert. Dies bedeutet ein verringertes Risiko für das Fortschreiten der Krankheit oder den Tod bei den Patienten. Diese Ergebnisse könnten wichtige Auswirkungen auf die Behandlung von Patienten haben.
Read more →INCYRiassunto: frontMIND, lo studio clinico cardine di Incyte ha dimostrato come la combinazione tafasitamab (Monjuvi®/Minjuvi®) sia in grado di prolungare notevolmente la sopravvivenza libera da progressione, riducendo il rischio di progressione della malattia...
Incyte's frontMIND clinical study demonstrated that the combination of tafasitamab (Monjuvi/Minjuvi) significantly prolongs progression-free survival in patients. This finding suggests a reduced risk of disease progression, marking a notable advancement in treatment options for patients. The results are expected to impact future therapeutic strategies.
Read more →INCYResumen: El ensayo fundamental frontMIND de Incyte demostró que la combinación con tafasitamab (Monjuvi®/Minjuvi®) prolongó significativamente la supervivencia libre de progresión, lo que reduce en un 25 % el riesgo de progresión de la enfermedad o muerte...
The frontMIND trial conducted by Incyte demonstrated that the combination of tafasitamab (Monjuvi/Minjuvi) significantly prolonged progression-free survival. This treatment reduced the risk of disease progression or death by 25%, indicating a positive outcome for patients. These results highlight the potential benefits of this combination therapy in clinical settings.
Read more →INCYSamenvatting: Cruciale frontMIND-studie van Incyte heeft aangetoond dat de combinatie van tafasitamab (Monjuvi®/Minjuvi®) de progressievrije overleving significant verlengde en het risico op ziekteprogressie of overlijden met 25% verlaagde bij patiënten met...
The frontMIND study by Incyte demonstrated that the combination of tafasitamab (Monjuvi/Minjuvi) significantly extended progression-free survival. Additionally, it reduced the risk of disease progression or death by 25% in patients. These findings highlight the potential benefits of this therapy for specific patient populations.
Read more →INCYIncyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
Incyte and Edison Scientific have announced a strategic collaboration to utilize the Kosmos AI platform in Incyte's research and development processes. This partnership aims to enhance decision-making and improve the efficiency of drug discovery and development through AI integration. The initial focus will be on target discovery and validation, with the potential for broader applications across Incyte's R&D efforts.
Read more →INCYSamenvatting: Incyte maakt bekend dat meer dan 20 abstracts zijn geselecteerd voor presentatie op het congres van de European Hematology Association (EHA) in 2026
Incyte announced that more than 20 abstracts have been selected for presentation at the European Hematology Association (EHA) conference in 2026. This significant participation underscores Incyte's ongoing research and contributions to the field of hematology. The event is expected to provide a platform for sharing important findings.
Read more →INCYIncyte gibt bekannt, dass mehr als 20 Abstrakte für die Präsentation auf dem Kongress der European Hematology Association (EHA) 2026 angenommen wurden
Incyte has announced that more than 20 abstracts have been accepted for presentation at the 2026 European Hematology Association (EHA) Congress. This achievement highlights the company's ongoing commitment to advancing research in hematology. The acceptance of these abstracts is a significant milestone for Incyte.
Read more →INCYIncyte annonce que plus de 20 résumés ont été retenus en vue d'une présentation lors du Congrès 2026 de l'Association européenne d'hématologie (EHA)
Incyte has announced that over 20 abstracts have been selected for presentation at the 2026 Congress of the European Hematology Association (EHA). This highlights the company's ongoing contributions to hematology research. Further details about the abstracts or their significance were not provided in the announcement.
Read more →INCYResumen: Incyte anuncia que logró la aceptación de más de 20 resúmenes para su presentación en el Congreso 2026 de la European Hematology Association (EHA)
Incyte has announced the acceptance of over 20 abstracts for presentation at the 2026 European Hematology Association Congress. This indicates the company's ongoing commitment to advancing research in hematology. The details of the abstracts and their implications for the field will be highlighted during the congress.
Read more →INCYRiassunto: Incyte rende noto che oltre 20 abstract sono stati accettati per la presentazione al Congresso 2026 della European Hematology Association (EHA)
Incyte has announced that over 20 abstracts have been accepted for presentation at the 2026 European Hematology Association Congress. This highlights the company's ongoing contributions to hematology research and its commitment to advancing scientific knowledge in the field.
Read more →INCYIncyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis
Incyte has released final 24-week data from the Phase 3 TRuE-AD4 trial, which assessed the efficacy and safety of Opzelura (ruxolitinib) cream in adults suffering from moderate atopic dermatitis. The study focused on patients who had inadequate responses to traditional treatments like topical corticosteroids and calcineurin inhibitors. The findings were presented at the 2026 EADV conference.
Read more →INCYIncyte gibt Langzeitdaten nach 24 Wochen aus der Phase-3-Studie TRuE-AD4 zur Opzelura® (Ruxolitinib)-Creme bei Erwachsenen mit mittelschwerer atopischer Dermatitis bekannt
Incyte has released long-term data from the Phase 3 TRuE-AD4 study regarding Opzelura® (Ruxolitinib) cream for adults with moderate atopic dermatitis. The study's findings are expected to provide insights into the treatment's efficacy and safety over a 24-week period. Further details on the results and implications for patients will be crucial for stakeholders.
Read more →INCYResumen: Incyte da a conocer los datos a largo plazo de 24 semanas del ensayo de fase III TRuE-AD4 de la crema Opzelura® (ruxolitinib) en adultos con dermatitis atópica moderada
Incyte has announced long-term data from the Phase III TRuE-AD4 trial of Opzelura® (ruxolitinib) for adults with moderate atopic dermatitis. The results cover a 24-week period, providing insights into the treatment's efficacy and safety. Further details on the findings were not disclosed in the article.
Read more →INCYIncyte annonce les données à long terme sur 24 semaines de l'essai de phase 3 TRuE-AD4 sur la crème Opzelura® (ruxolitinib) chez les adultes atteints de dermatite atopique modérée
Incyte has announced long-term data from the 24-week Phase 3 TRuE-AD4 trial of Opzelura (ruxolitinib) in adults with moderate atopic dermatitis. The study aims to evaluate the efficacy and safety of the cream in this patient population. Further details on the outcomes and implications of the trial are expected to be released.
Read more →INCYSamenvatting: Incyte maakt langetermijngegevens van 24 weken bekend uit de Fase 3 TRuE-AD4-studie van Opzelura® (ruxolitinib) crème bij volwassenen met matige atopische dermatitis
Incyte has released long-term data from the 24-week Phase 3 TRuE-AD4 study of Opzelura® (ruxolitinib) cream for adults with moderate atopic dermatitis. The study's findings are significant for understanding the treatment's efficacy and safety profile. Further details on the results were not provided in the article.
Read more →INCYRiassunto: Incyte annuncia dati a lungo termine relativi allo studio di fase 3 TRuE-AD4l di 24 settimana sulla crema Opzelura® (ruxolitinib) in soggetti adulti affetti da dermatite atopica moderata
Incyte has announced long-term data from the Phase 3 TRuE-AD4 study, which evaluated the efficacy of Opzelura® (ruxolitinib) cream in adults with moderate atopic dermatitis over a 24-week period. The results are expected to provide insights into the treatment's effectiveness and safety profile. Further details on the findings are anticipated.
Read more →INCYIncyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
Incyte has received FDA approval for Jakafi XR (ruxolitinib) extended-release tablets, which are indicated for the treatment of intermediate- or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. This approval allows for a once-daily dosing regimen, enhancing patient convenience. The decision is based on clinical studies demonstrating bioequivalence to the immediate-release formulation.
Read more →INCYResumen: Incyte anuncia la aprobación de la FDA para Jakafi XR™ (ruxolitinib) en comprimidos de liberación prolongada para tratar la mielofibrosis, la policitemia vera y la enfermedad de injerto contra huésped
Incyte has received FDA approval for Jakafi XR™, a prolonged-release formulation of ruxolitinib. This approval allows for the treatment of conditions such as myelofibrosis, polycythemia vera, and graft-versus-host disease. The new formulation aims to improve patient adherence to treatment regimens.
Read more →INCYSamenvatting: Incyte maakt bekend dat de FDA goedkeuring heeft verleend voor Jakafi XR™ (ruxolitinib) tabletten met vertraagde afgifte voor de behandeling van myelofibrose, polycythemia vera en graft-versus-hostziekte
Incyte has announced that the FDA has approved Jakafi XR™ (ruxolitinib) tablets for delayed release. This approval provides a new treatment option for patients suffering from myelofibrosis, polycythemia vera, and graft-versus-host disease. The approval is expected to enhance patient care in these conditions.
Read more →INCYIncyte annonce l’autorisation par la FDA des comprimés à libération prolongée Jakafi XR™ (ruxolitinib) pour le traitement de la myélofibrose, de la polycythémie vraie et de la maladie du greffon contre l’hôte
Incyte has received FDA approval for Jakafi XR™, an extended-release formulation of ruxolitinib. This approval allows for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. The new formulation is expected to enhance patient adherence and provide a significant advancement in treatment options.
Read more →INCYIncyte gibt die FDA-Zulassung von Jakafi XR™ (Ruxolitinib) Retardtabletten zur Behandlung von Myelofibrose, Polycythaemia vera und Graft-versus-Host-Erkrankung bekannt
Incyte has announced the FDA approval of Jakafi XR™ (Ruxolitinib) extended-release tablets. This approval allows the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. The introduction of Jakafi XR™ represents a significant advancement in therapeutic options for patients suffering from these conditions.
Read more →INCYRiassunto: Incyte annuncia l'approvazione dell'FDA di Jakafi XR™ (ruxolitinib) compresse a rilascio prolungato per il trattamento della mielofibrosi, della policitemia vera e della malattia del trapianto contro l'ospite
Incyte has received FDA approval for Jakafi XR™, an extended-release formulation of ruxolitinib. This new treatment option is indicated for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease. The approval is expected to enhance patient adherence to treatment regimens.
Read more →INCYIncyte Reports First Quarter 2026 Financial Results and Provides Business Updates
Incyte Corporation reported strong financial results for Q1 2026, with total revenue rising by 21% to $1.27 billion. The company highlighted significant growth in net sales of its key products, including Jakafi and Opzelura, while also noting anticipated product approvals in the coming year. Additionally, Incyte is advancing its late-stage pipeline with ten ongoing Phase 3 clinical trials, including pivotal studies for INCB161734. Despite these positive developments, rising costs associated with sales and R&D may present future challenges.
Read more →INCYIncyte präsentiert neue Phase-3-Daten zu Tafasitamab auf der Jahrestagung 2026 der American Society of Clinical Oncology (ASCO)
Incyte announced the presentation of complete results from the Phase 3 study of Tafasitamab for newly diagnosed diffuse large B-cell lymphoma at the 2026 ASCO annual meeting. The study, named frontMIND, shows promising outcomes that highlight Incyte's focus on advancing differentiated treatment options. The presentation will take place on May 30, 2026, in Chicago.
Read more →INCYSamenvatting: Incyte licht nieuwe gegevens van tafasitamab Fase 3 toe tijdens de 2026 ASCO (American Society of Clinical Oncology) Annual Meeting
Incyte announced that full results from the Phase 3 study of tafasitamab will be presented at the 2026 ASCO Annual Meeting. The study focuses on first-line treatment for diffuse large B-cell lymphoma (DLBCL). The positive results highlight Incyte's dedication to developing impactful therapies for patients.
Read more →INCYIncyte présente de nouvelles données de phase III sur le tafasitamab au congrès annuel 2026 de l’American Society of Clinical Oncology (ASCO)
Incyte announced that the full results of the Phase III frontMIND study evaluating tafasitamab will be presented at the 2026 ASCO annual meeting in Chicago. The study focuses on tafasitamab as a first-line treatment for newly diagnosed diffuse large B-cell lymphoma. Incyte's leadership expressed optimism about the potential impact of these results on patient care.
Read more →INCYRiassunto: Incyte evidenzia i nuovi dati su tafasitamab forniti dallo studio di fase 3 al Meeting annuale 2026 della American Society of Clinical Oncology (ASCO)
Incyte announced that complete results from the phase 3 clinical trial of tafasitamab will be presented at the 2026 ASCO Annual Meeting in Chicago. The study focuses on tafasitamab as a first-line treatment for diffuse large B-cell lymphoma (DLBCL). Positive results emphasize Incyte's commitment to advancing innovative treatment approaches.
Read more →INCYResumen: Incyte presenta nuevos resultados del estudio clínico en fase 3 de tafasitamab en el Congreso Anual 2026 de la American Society of Clinical Oncology (ASCO)
Incyte announced that the full results of its pivotal phase 3 study evaluating tafasitamab for first-line treatment in diffuse large B-cell lymphoma will be presented at the 2026 ASCO Annual Meeting. The study's positive results underscore Incyte's commitment to innovative treatment approaches. The conference will take place in Chicago from May 29 to June 2, 2026.
Read more →INCYIncyte to Report First Quarter 2026 Financial Results
Incyte has announced a conference call to discuss its first quarter financial results for 2026, scheduled for April 28 at 8:00 a.m. ET. The call will be accessible via a live webcast and will have a replay option available for thirty days. Incyte continues to highlight its focus on innovation in biopharmaceuticals.
Read more →INCYIncyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Incyte has presented positive 54-week data for povorcitinib, a JAK1 inhibitor, at the 2026 AAD Annual Meeting. The pivotal Phase 3 STOP-HS trials demonstrated significant improvements in patients with moderate to severe hidradenitis suppurativa (HS), with up to 71.4% achieving a key treatment response. The drug showed a manageable safety profile, supporting its potential as a first oral treatment option for HS.
Read more →INCYIncyte annonce de nouvelles données positives de dernière minute portant sur 54 semaines concernant le povorcitinib dans le traitement de l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD)
Incyte has announced new positive data regarding povorcitinib for treating hidradenitis suppurativa, presented at the 2026 American Academy of Dermatology annual meeting. The data covers a 54-week study period, showcasing the treatment's effectiveness. This presentation is expected to enhance the drug's visibility in the dermatology field.
Read more →INCYSamenvatting: Incyte maakt nieuwe positieve, recent bekendgemaakte gegevens over een periode van 54 weken bekend voor povorcitinib bij hidradenitis suppurativa tijdens de jaarlijkse bijeenkomst van de American Academy of Dermatology (AAD) in 2026
Incyte recently announced new positive data regarding povorcitinib for hidradenitis suppurativa at the 2026 American Academy of Dermatology meeting. The data covers a 54-week period, showcasing the drug's potential benefits. Further details on the findings and implications for treatment were shared during the event.
Read more →INCYResumen: Incyte anuncia nuevos datos positivos de última hora a las 54 semanas sobre el povorcitinib para la hidradenitis supurativa en el 2026 American Academy of Dermatology (AAD) Annual Meeting
Incyte has announced new positive data regarding povorcitinib for hidradenitis suppurativa, which will be presented at the 2026 American Academy of Dermatology Annual Meeting. The details of the data and its implications for treatment were not provided in the article. This update highlights Incyte's ongoing research efforts in dermatology.
Read more →INCYIncyte präsentiert neue positive 54-Wochen-Daten zu Povorcitinib bei Hidradenitis suppurativa auf der Jahrestagung 2026 der American Academy of Dermatology (AAD)
Incyte has presented new positive data regarding Povorcitinib for Hidradenitis suppurativa at the 2026 American Academy of Dermatology annual meeting. The data highlights a 54-week study, showcasing the drug's potential benefits. This presentation marks an important milestone for Incyte in the dermatology field.
Read more →INCYRiassunto: Incyte annuncia gli ultimi nuovi dati positivi ottenuti in 54 settimane su povorcitinib nell'idrosadenite suppurativa al Meeting annuale 2026 della American Academy of Dermatology (AAD)
Incyte announced new positive data on povorcitinib for hidradenitis suppurativa at the 2026 AAD Annual Meeting. The details of the findings were not provided in the article. The announcement highlights the company's ongoing research efforts in dermatology.
Read more →INCYIncyte Announces Executive Leadership Appointments
Incyte has announced several key executive leadership appointments to enhance its strategic focus and drive long-term growth. Dr. Pablo J. Cagnoni has been appointed as President and Global Head of Research and Development, while Dr. Steven Stein will serve as Executive Vice President and Chief Medical Officer. Mohamed Issa has also been appointed as Executive Vice President and Head of U.S. Commercial. These changes aim to support Incyte's ongoing innovation and operational effectiveness in the biopharmaceutical space.
Read more →INCYIncyte annonce des nominations au sein de sa haute direction
Incyte has announced new appointments within its senior management team. The changes are part of the company's ongoing strategy to enhance leadership and operational effectiveness. Specific details regarding the individuals appointed and their roles were not disclosed in the announcement.
Read more →INCYResumen: Incyte anuncia nuevos nombramientos en la dirección ejecutiva
Incyte has announced new appointments within its executive leadership team. The details regarding the specific roles and the individuals involved were not disclosed in the article. This change is part of the company's ongoing efforts to strengthen its leadership structure. Further information may be provided in future communications.
Read more →INCYRiassunto: Incyte annuncia le nomine dei dirigenti esecutivi
Incyte has announced new executive appointments, but the article provides no details about the individuals or their roles. The lack of information raises concerns about the transparency of the announcement. Overall, the article does not convey a positive outlook on the company's leadership changes.
Read more →INCYIncyte verkündet Ernennung von Führungspersonal
Incyte has announced a leadership appointment, although specific details about the new personnel or their roles were not provided. The announcement reflects the company's ongoing commitment to strengthen its management team. Further information may be released in subsequent communications.
Read more →INCYSamenvatting: Incyte kondigt benoemingen in het bestuursteam aan
Incyte has announced new appointments within its executive team. The article provides details about these changes, although specific names and roles are not mentioned. This move is likely aimed at strengthening the company's leadership structure.
Read more →INCYIncyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Incyte has received European Commission approval for Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel as the first-line treatment for advanced squamous cell carcinoma of the anal canal (SCAC). This approval is based on the POD1UM-303 study, which demonstrated significant improvements in progression-free survival. Zynyz is the first PD-1 immunotherapy approved in Europe for this indication, marking a significant advancement in treatment options for patients with advanced SCAC.
Read more →INCYIncyte to Present at Upcoming March 2026 Investor Conferences
Incyte has announced its participation in several investor conferences scheduled for March 2026. The presentations will be available via live webcast and can be replayed for 30 days. The company emphasizes its mission to address unmet medical needs through innovative therapeutics in Oncology and Inflammation & Autoimmunity.
Read more →INCY▼ -8.2%on this news
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results
Incyte reported strong financial results for Q4 and the full year 2025, highlighting significant growth in core business and pipeline advancements. The company achieved multiple regulatory approvals and plans to initiate 14 pivotal clinical trials by the end of 2026. Despite increased operating expenses and an asset impairment charge, Incyte maintains a positive outlook with substantial revenue guidance for 2026.
Read more →INCYIncyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
Incyte announced a positive opinion from the CHMP recommending Zynyz (retifanlimab) for first-line treatment of advanced squamous cell carcinoma of the anal canal. This recommendation is based on the results of the Phase 3 POD1UM-303 trial, which demonstrated significant efficacy in reducing the risk of disease progression. The opinion is now under review by the European Commission for final approval.
Read more →INCYIncyte to Report Fourth Quarter and Year-End 2025 Financial Results
Incyte has announced the scheduling of its fourth quarter and year-end 2025 financial results conference call for February 10, 2026. The call will be accessible via a live webcast and will include a replay option for those unable to attend. Incyte continues to focus on developing innovative therapeutics for unmet medical needs.
Read more →INCYIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
Incyte announced positive topline results from the Phase 3 frontMIND trial, which evaluated tafasitamab combined with lenalidomide and R-CHOP for first-line treatment of diffuse large B-cell lymphoma (DLBCL). The trial met its primary endpoint of progression-free survival, indicating potential benefits for newly diagnosed patients. Incyte plans to submit a supplemental Biologics License Application in the first half of 2026.
Read more →INCYIncyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
Incyte announced that the European Commission has approved Minjuvi (tafasitamab) in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma. This approval marks a significant advancement in treatment options for patients in Europe, addressing a critical need for effective therapies. The decision follows positive trial results demonstrating improved progression-free survival compared to placebo.
Read more →INCY▼ -5.7%on this news
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
Incyte announced positive preliminary data from two Phase 1 studies of INCA033989, a first-in-class monoclonal antibody targeting mutant calreticulin in myelofibrosis patients. The results, presented at the ASH 2025 Annual Meeting, indicate significant spleen volume reductions and symptom improvements. Incyte plans to initiate a registrational program for INCA033989 in 2026.
Read more →INCY▼ -5.7%on this news
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
Incyte announced that the FDA has granted Breakthrough Therapy designation to INCA033989, a monoclonal antibody targeting mutant calreticulin for essential thrombocythemia patients resistant to prior therapies. This designation aims to expedite the drug's development, with a Phase 3 program planned for mid-2026. Preliminary Phase 1 data indicates promising efficacy and tolerability.
Read more →INCYIncyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
Incyte has partnered with supermodel Winnie Harlow to launch 'The Power of Choice' campaign, aimed at raising awareness about vitiligo. Harlow, who has lived with the condition, shares her personal experiences and encourages others to understand and manage vitiligo. The initiative seeks to empower individuals affected by vitiligo to explore their options and engage with healthcare professionals.
Read more →INCYIncyte Appoints Richard Hoffman as Executive Vice President and General Counsel
Incyte has appointed Richard Hoffman as Executive Vice President and General Counsel, effective December 1, 2025. Hoffman, who has over 20 years of experience, will oversee the company's legal and compliance teams. He succeeds Sheila Denton, who is leaving for new opportunities. Hoffman's background includes significant roles in corporate governance and business development.
Read more →INCYIncyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
Incyte reported strong financial results for Q3 2025, with total revenues reaching $1.37 billion, a 20% increase from the previous year. Key products Jakafi and Opzelura contributed to this growth, demonstrating solid demand. The company has raised its full-year revenue guidance, anticipating net product revenue will fall between $4.23 billion and $4.32 billion. Incyte is prioritizing pipeline development while also facing challenges, including rising costs and the suspension of certain projects.
Read more →INCY▲ +10.3%on this news
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates
Incyte has reported strong financial results for the second quarter of 2025, with total revenues reaching $1,216 million, reflecting a 16% increase year-over-year. The company raised its full-year guidance for Jakafi and other oncology products, signifying robust sales performance. Notably, the FDA approved Zynyz and Monjuvi for specific cancers, enhancing Incyte's treatment portfolio. The newly appointed CEO, Bill Meury, expressed confidence in the company's growth trajectory and upcoming clinical trials, although there is a minor setback with the extended FDA review of Opzelura for pediatric use.
Read more →INCYIncyte Reports 2025 First Quarter Financial Results and Provides Updates
Incyte reported strong financial results for Q1 2025, with total revenues reaching $1,053 million, reflecting a 20% increase year-over-year. The company's flagship product, Jakafi, generated $709 million in net revenues, alongside a successful launch of Niktimvo. Positive clinical data for povorcitinib in chronic spontaneous urticaria highlights its potential across multiple indications. Overall, Incyte remains on track to meet its full-year objectives amid robust product demand and ongoing clinical advancements.
Read more →INCY▼ -7.9%on this news
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results,
Incyte reported strong financial results for Q4 2024 and the full year, with total revenues reaching $1.2 billion in the fourth quarter, a 16% increase year-over-year. The company anticipates significant growth in 2025, backed by guidance for strong product performance, including expected sales of Jakafi and Opzelura. Notably, Incyte plans to achieve several important milestones, including multiple product launches and pivotal study readouts. The completion of bioequivalence for ruxolitinib XR is set to support future FDA submissions.
Read more →INCY▲ +12%on this news
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates
Incyte reported its financial results for the third quarter of 2024, highlighting significant revenue growth and advancements in its clinical pipeline. The company achieved a total revenue of $1,138 million, with notable increases in revenues from Jakafi and Opzelura. Additionally, Incyte announced the FDA approval of Niktimvo for chronic graft-versus-host disease and provided updates on ongoing clinical trials for various treatments, including ruxolitinib cream for pediatric atopic dermatitis. The company continues to demonstrate strong performance and aims for impactful launches by 2030.
Read more →INCYIncyte Reports 2024 Second Quarter Financial Results and Provides Updates
Incyte reported its 2024 second quarter financial results, showcasing a 9% revenue increase to over $1 billion, primarily driven by strong demand for Opzelura and Jakafi. The company has acquired Escient Pharmaceuticals, focusing on innovative R&D programs. While the revenue growth was notable, it was tempered by higher channel inventory levels. Furthermore, positive Phase 3 trial results for retifanlimab were highlighted, which the company plans to present in detail later this year.
Read more →INCY▲ +8.6%on this news
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock - Incyte commences Dutch Auction tender offer to repurchase up to $1.67 billion of outstanding common shares
Incyte Corporation announced the approval of a $2 billion share repurchase authorization and initiated a modified Dutch Auction tender offer to repurchase up to $1.67 billion of its common stock. The company aims to enhance shareholder value, citing its strong balance sheet and confidence in its business outlook. Additionally, a separate agreement was made with certain board members to repurchase up to $328 million of stock to maintain their ownership percentage. The tender offer will conclude on June 10, 2024, unless extended.
Read more →INCYIncyte Reports 2024 First Quarter Financial Results and Provides Updates
Incyte reported its first quarter financial results for 2024, showing a total revenue increase of 9% year-over-year, driven by patient demand for its products Jakafi and Opzelura. Net revenues for Jakafi were reported at $572 million, while Opzelura achieved $86 million, reflecting a significant 52% increase year-on-year. The company also announced an acquisition of Escient Pharmaceuticals to bolster its pipeline and facilitate further developments in mast cell-mediated diseases. Additionally, Incyte is progressing with multiple pivotal studies, including ongoing Phase 1 trials for new inhibitors and the FDA's Priority Review for axatilimab in treating chronic graft-versus-host disease.
Read more →INCYIncyte Reports 2023 Fourth Quarter and Year-End Financial Results,
Incyte has reported a successful fourth quarter and year-end financial results for 2023, achieving total net product and royalty revenues of $3.7 billion, a 14% increase year-over-year. The company has also highlighted strong performance from its drug Jakafi and the launch of Opzelura, which showed promising growth in atopic dermatitis and vitiligo markets. Looking forward, Incyte plans to advance its pipeline with potential launches slated for more than 10 new therapies by 2030. Challenges include negative impacts on quarterly revenues due to increased free product distributions under Medicare and awaiting price negotiations in France for Opzelura.
Read more →INCYIncyte Reports 2023 Third Quarter Financial Results and Provides Updates
Incyte Corporation reported its financial results for Q3 2023, highlighting a total revenue of $919 million, a 12% increase from the previous year. The company saw significant growth in its key product Jakafi, with revenues of $636 million, while Opzelura experienced a remarkable 141% increase year-over-year. Additionally, the Phase 2 study for povorcitinib in prurigo nodularis met its primary endpoint, prompting plans for a Phase 3 trial in 2024. Incyte's robust performance reflects strong patient demand and favorable payer coverage across its treatment portfolio.
Read more →INCYIncyte Reports 2023 Second Quarter Financial Results and Provides Updates
Incyte reported its 2023 second quarter financial results, showcasing strong growth with total net product revenues of $827 million, a 25% increase year-over-year. Significant contributions came from Jakafi and Opzelura, with revenues of $682 million and $80 million, respectively. The company raised its full-year guidance following these results and provided updates on their key clinical trials, indicating positive outcomes for ruxolitinib cream in pediatric atopic dermatitis and axatilimab in chronic graft-versus-host disease. Incyte is optimistic about its advancing pipeline, with multiple studies ongoing in various indications.
Read more →INCY▼ -7.1%on this news
Incyte Reports 2023 First Quarter Financial Results and
Incyte announced its first quarter financial results for 2023, revealing a 14% increase in total net product revenues totaling $693 million. The growth was primarily driven by Jakafi and the successful launch of Opzelura, which has recently been approved for treating vitiligo in Europe. Despite positive performance, Incyte faced challenges, including increased deductions affecting net revenues and the discontinuation of several clinical trials. The company aims to focus on its most promising programs to enhance future growth.
Read more →INCYIncyte Reports 2022 Fourth Quarter and Year-end Financial Results,
Incyte has reported its financial results for the fourth quarter and year-end 2022, showing an 18% increase in net product revenues to $2.75 billion. The company provided positive financial guidance for 2023, expecting Jakafi net revenues to range between $2.53 and $2.63 billion. The strong market position of Opzelura in atopic dermatitis and vitiligo has been highlighted, reflecting robust demand. Moreover, updates on several key clinical trials have indicated continued progress in Incyte's development pipeline.
Read more →INCYIncyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key -Total net product revenues grew to $713 million (+20% Y Y) as a result of strong Jakafi (ruxolitinib) and Opzelura (ruxolitinib) cream net product revenues -Jakafi net product revenues of $620 mill
Read more →INCY▼ -6.2%on this news
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Total revenues increased 29% year-over-year (Y/Y) to $911 million; total product revenues of $664
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT WILMINGTON, Del. - August 2, 2022 - Incyte (Nasdaq:INCY) today reports 2022 second quarter financial results, and provides a status upda
Read more →INCYIncyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs - Total product and royalty revenues of $728 million in Q1'22 (+20% Y/Y) - Jakafi (ruxolitinib) net
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT WILMINGTON, Del. - May 3, 2022 - Incyte (Nasdaq:INCY) today reports 2022 first quarter financial results, and provides a status update on
Read more →INCYIncyte Reports 2021 Fourth Quarter and Year-end Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs - Total product and royalty revenues of $813 million (+20
Incyte Reports 2021 Fourth Quarter and Year-end Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT WILMINGTON, Del. - February 8, 2022 - Incyte (Nasdaq:INCY) today reports 20
Read more →INCY▼ -8.5%on this news
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs - Total product and royalty revenues of $778 million in Q3 2021 (+25% vs. Q3 2020); Jakafi (ruxoliti
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT WILMINGTON, Del. - November 2, 2021 - Incyte (Nasdaq:INCY) today reports 2021 third quarter financial results and prov
Read more →INCY▼ -8.5%on this news
Corporate Statement Regarding Opzelura (ruxolitinib) Cream
Corporate Statement Regarding Opzelura WILMINGTON, Del. - November 2, 2021 - This morning, as part of our Q3 2021 earnings call, we addressed a question related to samples and commercial supply of Opzelura (ruxolitinib) As of today, we have received three product complaints re
Read more →INCYIncyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Total product and royalty revenues of $696 million in Q2 2021 (+17% vs Q2 2020) - Jakafi (ruxolit
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT WILMINGTON, Del. - August 3, 2021 - Incyte (Nasdaq:INCY) today reports 2021 second quarter financial results and prov
Read more →INCYIncyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs - Total product and royalty revenues of $605 million in Q1 2021 (+6% vs Q1 2020) - Jakafi (ruxolitin
Incyte Reports 2021 First Quarter Financial and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today at WILMINGTON, Del. - May 4, 2021 - Incyte (Nasdaq: INCY) today reports 2021 first quarter financial results, and provides a status update on
Read more →INCYIncyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs - Total FY revenues of $2.67 billion (+24% y/y); total FY pro
Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today WILMINGTON, Del. - February 9, 2021 - Incyte (Nasdaq: INCY) today reports 2020 fourth quarter
Read more →INCYIncyte Reports 2020 Third Quarter Financial Results and Provides Updates on Key Clinical Programs - Total product and royalty revenues of $621 million (+16% vs Q3 2019) for the quarter ended
Incyte Reports 2020 Third Quarter Financial and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today WILMINGTON, Del. - November 5, 2020 - Incyte (Nasdaq: INCY) today reports 2020 third quarter financial results, and provides a status update o
Read more →INCYIncyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs - Total product and royalty revenues of $593 million (+16% vs Q2 2019) for the quarter ended
Incyte Reports 2020 Second Quarter Financial and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today WILMINGTON, Del. - August 4, 2020 - Incyte (Nasdaq: INCY) today reports 2020 second quarter financial results, and provides a status update
Read more →INCYIncyte Reports 2020 First Quarter Financial Results and Provides Updates on Key Clinical Programs - Total product and royalty revenues of $569 million (+24% vs Q1 2019) for the quarter ended
Incyte Reports 2020 First Quarter Financial and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today WILMINGTON, Del. - May 5, 2020 - Incyte (Nasdaq: INCY) today reports 2020 first quarter financial results, and provides a status update on th
Read more →INCYIncyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs - Total product and royalty revenues of $579 million (+24%
Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today at 8:00 a.m. EST WILMINGTON, Del. - February 13, 2020 - Incyte (Nasdaq:INCY) today reports 2019 fourth quarter a
Read more →INCYPlanegg/Munich, Germany, and Wilmington, Delaware, U.S.
Planegg/Munich, Germany, and Wilmington, Delaware, U.S., January MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab - MorphoSys and Incyte to co-commercialize tafasitamab in the U.S. - Incyte has exclusive commercialization rights outside of
Read more →INCYIncyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs - Total product and royalty revenues of $534 million (+24% vs. Q3 2018) and Jakafi (ruxolitinib) revenues of $433 million
Incyte Reports 2019 Third Quarter Financial and Provides Updates on Key Clinical Programs Conference Call and Webcast Scheduled Today WILMINGTON, Del. - October 29, 2019 - Incyte Corporation (Nasdaq:INCY) today reports 2019 third quarter financial results and provides a statu
Read more →INCYIncyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs Total product and royalty revenues of $510 million (+21% vs. Q2 2018) and Jakafi (ruxolitinib) revenues of $410 million (
Incyte Reports 2019 Second Quarter Financial Results and Provides Updates on Key Clinical Programs Total product and royalty revenues of $510 million (+21% vs. Q2 2018) and Jakafi (ruxolitinib) revenues of $410 million (+18% vs. Q2 2018) for the quarter ended June 30, 2019; rai
Read more →INCYIncyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for
Incyte Reports 2019 First Quarter Financial Results and Provides Updates on Key Clinical Programs Total revenues of $498 million (+30% vs Q1 2018) and total product-related revenues of $458 million (+20% vs Q1 2018) for the quarter ended March 31, 2019 Jakafi (ruxolitinib) rev
Read more →INCYIncyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs Total product-related revenues of $468 million (+25%) in 4Q 2018 and $1.7
Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs Total product-related revenues of $468 million (+25%) in 4Q 2018 and $1.7 billion (+25%) for the full year 2018 Jakafi (ruxolitinib)
Read more →Competitive Position
How INCY ranks across every disease it competes inCompetitive Position is a premium feature
See how INCY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial